Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Nasdaq: AGIO
    
Analyst Coverage
FirmAnalyst
Canaccord GenuityJohn Newman, Ph.D.
CowenEric Schmidt, Ph.D.
Credit SuisseAlethia Young
Goldman SachsTerence Flynn, Ph.D.
Janney Montgomery Scott Debjit Chattopadhyay
JP MorganAnupam Rama
Leerink Swann & CompanyMichael Schmidt, Ph.D.
Needham & CompanyChad Messer, Ph.D.
Oppenheimer & Co.Leah Rush Cann
SunTrust Robinson HumphreyYatin Suneja
Agios Pharmaceuticals Inc is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Agios Pharmaceuticals Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Agios Pharmaceuticals Inc or its management. Agios Pharmaceuticals Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.